CymaBay's seladelpar has the potential to raise the bar in treatment for PBC
Results from a phase 3 trial looking at treatment for primary biliary cholangitis (PBC) are 'genuinely exciting' and support the potential for seladelpar to raise the bar in treatment of the disease.